Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06378502
Other study ID # antibiotic-resistence
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date May 3, 2024
Est. completion date June 30, 2026

Study information

Verified date April 2024
Source Universita degli Studi di Genova
Contact Maria Menini
Phone 3396598789?
Email maria.menini@unige.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present project (non-inferiority trial) is to evaluate the effect of different antibiotic strategies (long-span vs. short-span) for implant surgery on peri-implant tissue health, oral microbiome (included resistome) and salivary MiRNomics in healthy patients.


Description:

A total of 80 patients will be included and randomly divided in two groups: 1. Long-span prescription: 1 g Amoxicillin every 8 h starting 1 day before surgery and for 5 days after surgery 2. Short-span prescription: 2 g Amoxicillin 1 h before surgery Before surgery, patients will undergo an antibiotic sensitivity test (AST), and non-invasive samples will be taken to analyse oral microbiome including resistome. Saliva samples will be also taken for miRNomics analysis. Patients will be rehabilitated with single implants or partial implant-supported fixed prostheses. The day of surgery, samples of peripheral blood will be taken and peripheral blood mononuclear cells (PBMCs) isolated from the first 30 patients in order to implement a micro-fluidic bioreactor replicating the bone healing process of each patient. 3D bone models will be developed that are suitable for drug screening. At 2 and 6 months post-treatment, AST test and oral microbiome and resistome analysis will be performed again. 2 months after treatment, a new saliva sample of the patients will be also taken, analysed and compared using MiRnomics technology with the preoperative one with the further aim of identifying reliable biomarkers of mucositis and perimplantitis. During the 12-month follow-up implant survival rate, marginal bone loss (MBL), biologic and technical complication rate and peri-implant health parameters (including plaque index, probing depth and bleeding on probing) will be evaluated. Parametric or non-parametric comparative tests, as appropriate, will be performed to detect differences between the groups in the various outcome variables. The effect of patient-related and implant-related predictive factors on the various outcomes will be evaluated using multilevel logistic regression analysis. Metadata will be analyzed also with 4th generation Artificial Neural Networks (ANNs) (machine learning) using unsupervised and supervised systems. Expected results: The present project is expected to clarify if the short-span antibiotic therapy is not inferior to the long-span one in healthy patients undergoing implant surgery. The outcomes will contribute to the development of effective clinical guidelines that will help to tackle the issue of antimicrobial resistance. In addition, the development and validation of a 3D bone model to be used for drug screening is expected, that might overcome limitations of currently available 2D bone models and animal studies. A further expected result is the identification of biomarkers for diagnosis and prognosis in implant dentistry, through salivary miRNomics that might lead to the development of a non-invasive liquid biopsy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date June 30, 2026
Est. primary completion date December 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: Healthy volunteers requiring one single implant or partial implant-supported rehabilitation in an edentulous area of the posterior mandible or maxilla Exclusion Criteria: - Patients unable to commit to follow-up - General contraindications to implant surgery - Immuno-suppressed/immune-compromised patients - Patients irradiated in the head and/or neck - Uncontrolled diabetes - Pregnancy, childbearing potential, breastfeeding - Smoking habit - Untreated periodontal disease (Caton et al, J Clin Periodontol 2018) - Poor oral hygiene and motivation (plaque index > 20%) - Addiction to alcohol or drugs - Psychiatric problems and/or unrealistic expectations - Patients with an acute infection (abscess) or suppuration in the site intended for implant placement - Patients treated or under treatment with intravenous amino-bisphosphonates - Patients referred only for implant placement if the follow-up cannot be done at the treatment center - Patients participating in other studies, if the present protocol could not be fully adhered to - Patients with allergy/hypersensitivity to penicillin or drug excipients - Patients recently treated with antibiotics for other indications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amoxicillin Short
Short Span
Amoxicillin Long
Long span

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Universita degli Studi di Genova

Outcome

Type Measure Description Time frame Safety issue
Primary Mean peri-implant bone loss bone loss at 6 and 12 months after prosthesis delivery
Secondary Incidence of biological and technical complications at the implant site complications 12 months
Secondary implant survival rate CSR 12 months
Secondary Antibiotic sensitivity sensitivity 1 week before and 2 months and 6 months after implant insertion
Secondary Peri-implant myco-, microbiome and resistome resistome 1 week before and 2 months and 6 months after implant insertion
Secondary Salivary miRNomics miRNomics 1 week before and 2 months after implant insertion
Secondary Adverse reactions reaction during the entire follow-up period
Secondary Development of a 3D bone model 3D bone model 1 year
Secondary Plaque index (PI) measured on 6 surfaces each tooth - percentage value 3, 6 and 12 months after prosthesis delivery
Secondary Bleeding on probing (BOP) measured on 6 surfaces each tooth - percentage value 3, 6 and 12 months after prosthesis delivery
Secondary Peri-implant pocket probing depth (PPD) measured on 6 surfaces each tooth - percentage value 3, 6 and 12 months after prosthesis delivery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04976829 - Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO)
Completed NCT04146142 - Transperineal MRI-TRUS Fusion Guided Prostate Biopsy With vs Without Antibiotic Prophylaxis N/A
Completed NCT04203784 - Meropenem and Piperacillin Plasma Concentrations During CRRT
Completed NCT03408457 - Influence of Perioperative Fluid Balance on Serum Concentrations of Antibiotics and Surgical Site Infections
Recruiting NCT05420168 - Antibiotic Prescription Relevance Indicators: Calculation From Electronic Health Records
Completed NCT03085459 - Effects of Nursing Staff on Empiric Antibiotic in Septic Shock N/A
Completed NCT03405168 - Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer Phase 2
Recruiting NCT03897582 - Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
Recruiting NCT03583749 - Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years
Recruiting NCT04546815 - The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.
Recruiting NCT03563586 - Mechanical Bowel Preparation With or Without Oral Antibiotics for Colorectal Cancer Surgery N/A